Cite

HARVARD Citation

    Gopal, A. et al. (n.d.). A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. Hematological oncology. p. 260. [Online]. 
  
Back to record